Cipher Pharmaceuticals (TSE:CPH) Shares Cross Below Fifty Day Moving Average – Time to Sell?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$17.21 and traded as low as C$16.38. Cipher Pharmaceuticals shares last traded at C$16.41, with a volume of 11,515 shares.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group set a C$17.00 target price on Cipher Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of C$17.00.

Cipher Pharmaceuticals Stock Performance

The firm’s 50 day moving average price is C$17.21 and its two-hundred day moving average price is C$16.16. The firm has a market cap of C$416.67 million, a PE ratio of 13.79 and a beta of 1.10. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.67 and a current ratio of 1.25.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its quarterly earnings results on Thursday, May 7th. The company reported C$0.33 EPS for the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. The firm had revenue of C$17.39 million for the quarter. On average, research analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.